Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Diet-treated subjects and/or subjects with type 2 diabetes in OAD (oral anti-diabetic drug) mono-therapy~* HbA1c for diet-treated subjects: HbA1c between 6.5-10.0% (both inclusive) and for OAD treated subjects: HbA1c between 6.5-9.5% (both inclusive)~* Body mass index (BMI) between 27-40 kg/m\^2 (both inclusive)~* Subjects should have a stable body weight for at least 3 months prior to screening (as documented by a weight within 3 to 6 months, prior to screening that is within 15% of the screening weight)~* Euthyroid subjects~* Subjects should be unrestrained eaters~Exclusion Criteria:~* Recurrent severe hypoglycaemia~* Impaired liver function~* Impaired renal function~* Cardiac problems~* Uncontrolled treated/untreated hypertension~* Known or suspected allergy to trial products or related products~* Use of any drug (except for OADs), which in the investigator's opinion could interfere with the subject's glucose level or body weight~* Active hepatitis B and/or active hepatitis C~* Positive HIV (human immunodeficiency virus) antibodies~* Known or suspected abuse of alcohol or narcotics~* Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, cola drinks, chocolate) as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lira --> placebo (Type: EXPERIMENTAL): None
- Placebo --> glim (Type: PLACEBO_COMPARATOR): None
- Glim --> lira (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).